{
    "nct_id": "NCT04115306",
    "official_title": "Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer",
    "inclusion_criteria": "Inclusion Criteria, Combination with fulvestrant (Part 3):\n\n* RSK2 positive from available archival or fresh tumor tissue (FFPE).\n* Histologically or cytologically diagnosed HR+, HER2-\n* Diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amendable to resection or radiation with curative intent or metastatic disease not amendable to curative therapy\n* Must be appropriate candidates for endocrine therapy\n* Previously received at least 1 line of endocrine therapy for MBC or had recurrence while on adjuvant endocrine therapy for locally advanced breast cancer\n* Discontinued endocrine therapy at least 15 days prior to first dose of PMD-026\n* At least 1 measurable target lesion as defined by RECIST v1.1\n* Progression on or after treatment with a CDK4/6 inhibitor in combination with endocrine therapy inhibitor in the locally advanced or metastatic setting\n* Adequate hematologic, hepatic, and renal function as assessed by laboratory parameters\n* Toxicity related to prior therapy resolved to at least Grade 1 (alopecia excepted) or to at least Grade 2 with prior approval of the Medical Monitor\n\nExclusion Criteria, Combination with fulvestrant (Part 3):\n\n* ≤14 days from prior chemotherapy, biological or investigational therapy\n* Prior fulvestrant in the locally advanced or metastatic setting\n* Presence of visceral crisis or uncontrolled visceral disease for which chemotherapy would be indicated\n* Central nervous system metastases, unless appropriately treated and neurologically stable\n* History of leptomeningeal metastases\n* Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n* Known hepatitis B or hepatitis C infection\n* Known HIV-positive with CD4+ cell counts <350 cells/μL\n* Known HIV-positive with a history of an AIDS-defining opportunistic infection\n* History of clinically significant cardiovascular abnormalities, including QTcF interval >460 msec (using Fridericia's formula)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}